Bcl-2 and MDM2 Inhibitor Combination for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medical treatments for cancer often rely on single-drug therapies that can be ineffective due to their reliance on a single signaling pathway, leading to drug resistance and significant side effects, highlighting the need for combination therapies targeting multiple pathways to enhance efficacy and reduce toxicity.
Innovation Solution
A combination product comprising a Bcl-2 inhibitor and an MDM2 inhibitor, specifically formulated compounds or their pharmaceutically acceptable salts, administered alone or in combination, to target and inhibit key proteins involved in apoptosis and cell cycle regulation, potentially synergizing to treat various cancers, including hematological malignancies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-drug therapy is used, then treatment simplicity is maintained, but anti-tumor efficacy is insufficient and drug resistance occurs
Solution Approach 1:
The patent combines Bcl-2 inhibitor and MDM2 inhibitor into a fixed-dose combination product, merging two separate therapeutic agents into a single administered unit. This approach enhances anti-tumor efficacy by targeting multiple pathways simultaneously while simplifying the treatment regimen for patients, as they receive both drugs in a single dose rather than managing separate therapies.
Solution Approach 2:
The invention creates a composite pharmaceutical product containing two distinct active ingredients (Bcl-2 inhibitor and MDM2 inhibitor) with different mechanisms of action. This composite formulation allows the drugs to work synergistically against tumor cells through multiple pathways, overcoming the limitations of single-agent therapy while maintaining a unified treatment approach.
2Reliability
If high dose single drug is administered, then anti-tumor activity is increased, but side effects increase significantly
Solution Approach 1:
The patent divides the anti-tumor therapeutic effect into two separate components: Bcl-2 inhibitor targeting apoptosis regulation and MDM2 inhibitor targeting cell cycle control. By segmenting the therapeutic approach into two lower-dose agents working together, the treatment achieves comparable or superior anti-tumor activity to high-dose monotherapy while reducing the toxic side effects associated with high single-drug doses.
Solution Approach 2:
The fixed-dose combination allows for optimization of the dose ratio between Bcl-2 inhibitor and MDM2 inhibitor, changing the dosing parameters from high single-agent doses to lower combined doses. This parameter adjustment maintains effective anti-tumor activity while reducing the harmful effects that occur with high-dose single drug administration.
3Reliability
If combination therapy is used, then anti-tumor efficacy is enhanced, but treatment complexity increases
Solution Approach 1:
The patent merges two complex therapeutic agents into a single fixed-dose combination product, maintaining enhanced anti-tumor efficacy through dual mechanism action while simplifying treatment administration. Patients receive both drugs in a single dose, eliminating the need to manage separate therapies, monitor individual dosing schedules, or coordinate multiple medications, thus preserving ease of operation despite the combination approach.
4Reliability
If single signaling pathway targeting is used, then drug specificity is maintained, but drug resistance develops
Solution Approach 1:
The invention creates a composite therapeutic approach targeting two distinct signaling pathways: the Bcl-2 apoptosis pathway and the MDM2-p53 cell cycle pathway. This multi-pathway strategy prevents drug resistance by attacking tumor cells through multiple mechanisms simultaneously, making it harder for resistant clones to emerge, while the fixed-dose formulation manages the complexity of multi-pathway targeting in a unified treatment regimen.
Data Source
AI summary
Provided herein is a combination product comprising a Bcl-2 inhibitor and an MDM-2 inhibitor, the combination product providing a use in the prevention and/or treatment of diseases (e.g., cancer).